Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
A phase 1/2 trial of Zilovertamab vedotin in diffuse large b-cell lymphoma and burkitt lymphoma, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) is a phase 1/2 interventional study registered as NCT06395103 by Merck Sharp & Dohme LLC, with 90 participants planned, started 2024-08-16 and due to reach its primary completion in 2029-03-31. Interventions recorded: Zilovertamab vedotin. Conditions listed: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Shares Zilovertamab vedotin, Merck & Co. (MSD).
- TrialA Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
Shares Zilovertamab vedotin, Merck & Co. (MSD), Diffuse large B-cell lymphoma.
- TrialwaveLINE-003
- TrialSepantronium Bromide for the Treatment of High-grade B-cell Lymphoma
- TrialA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituxi
Shares Zilovertamab vedotin, Merck & Co. (MSD), Diffuse large B-cell lymphoma.
- TrialA Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Shares Zilovertamab vedotin, Merck & Co. (MSD), Diffuse large B-cell lymphoma.
- TrialA Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-
Shares Zilovertamab vedotin, Merck & Co. (MSD).
- TargetXanthine oxidase (XDH)